Glyscend Ther­a­peu­tic­s' ear­ly da­ta show poly­mer mim­ics ben­e­fits of surgery in type 2 di­a­betes, obe­si­ty

Glyscend Ther­a­peu­tics re­leased topline da­ta for its poly­mer tar­get­ing type 2 di­a­betes and obe­si­ty to­day, with the hopes the can­di­date will have the same ef­fects as bariatric surgery with­out com­pli­ca­tions from the in­va­sive stan­dard-of-care pro­ce­dures.

The oral gut-tar­get­ing poly­mer, dubbed GLY-200, showed sig­nif­i­cant and clin­i­cal­ly rel­e­vant re­duc­tions in glu­cose af­ter eat­ing and a de­crease in body weight and food in­take in the 51 par­tic­i­pants in the com­pa­ny’s Phase IIa tri­al. Pa­tients took ei­ther the poly­mer or a place­bo twice dai­ly for 14 days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER